Asthma Therapeutics Pipeline Analysis 2017

Asthma Therapeutics Pipeline Analysis

The pipeline for asthma therapeutics is expected to experience a positive trend in the future, the increase is mainly attributable to decreasing air quality. The prevalence of asthma is increasing globally due to the factors including environmental factors, genetic factors, air pollution, less physical activity and smoking. These factors contribute immensely in driving the pipeline analysis for asthma. According to World Health Organization, around 235 million people suffered from asthma, in 2013. Asthma related deaths occurs more commonly in low and lower middle income countries. Asthma is a very common disease and the treatment options available for the same are expensive. It has been also notes that the disease is more prevalent in women as compared to men.

Explore Report at: https://www.psmarketresearch.com/market-analysis/asthma-therapeutics-pipeline-analysis

Asthma is a chronic disease that involves inflammation of bronchial tubes. Bronchial tubes allow air to pass through the lungs and when the lungs get inflamed muscles tend to become stiff, resulting in various symptoms that might be experienced by the patient. The inflammation of bronchial tubes affects the air passage which results in the occurrence of symptoms including breath shortening, wheezing, coughing and chest congestion. These symptoms are usually very active during physical activities such as exercising, walking and running. People with family history of asthma have more chances to develop asthma. There is no cure of asthma, but various treatment options can help to improve the quality of life of patient. Along with the common symptoms of asthma, pattern of symptoms occurrence is also important during diagnosis. Patterns usually include during exercise, during particular season and morning or night. Asthma can be diagnosed by analysing the patient’s family history and certain breathing tests such as spirometry. Asthma cannot be cured but the disease can be dealt with its proper management. . There are certain marketed drugs that are used in the form of inhalation for managing asthma include inhaled corticosteroids, budesonide, mometasone, ciclesonide, flunisolide and beclomethasone.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/asthma-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of asthma therapeutics include Regeneron Pharmaceuticals, Inc., Novartis AG, Chiesi Farmaceutici S.p.A., GlaxoSmithKline plc, AstraZeneca plc, Merck Sharp & Dohme Corp., Mundipharma Research Limited, Actavis Inc., Sanofi, AbbVie, Inc., Boehringer Ingelheim GmbH, Genentech, Inc., Rhizen Pharmaceuticals SA.

Advertisements

Sjögren’s Syndrome Therapeutics Pipeline Analysis, 2017 – Designation, Collaboration and Other Developments

Sjögren_s Syndrome Therapeutics Pipeline

The study analyzed that Sjögren’s syndrome pipeline comprises of approximately 42 drug candidates in different stages of development. Sjögren’s syndrome is a chronic inflammatory disease, which leads to infiltration of lacrimal and salivary glands. It is mostly associated with sicca symptoms, which include dry eyes (xeropthalmia) and dry mouth (xerostomia). It is also associated with other autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. The treatment approaches for this disease mostly include monoclonal antibodies and small molecules, which are being developed to target and reduce the inflammatory mediators. Clinical presentation can vary considerably from relatively mild sicca symptoms, fatigue and arthralgia to severe systemic symptoms such as glomerulonephritis, vasculitis and a host of neurological manifestations.

Browse Report Description at: https://www.psmarketresearch.com/market-analysis/sjogrens-syndrome-therapeutics-pipeline-analysis

The positive results of the drug candidates are speeding up the drug development process for Sjögren’s syndrome. In August 2016, Aldeyra Therapeutics, Inc. presented the positive Phase II results of NS2, a 1% dermatologic cream under Phase II stage of development for Sjögren’s syndrome. Six of six (100%) subjects treated with NS2 improved over the course of therapy as assessed by central review, and the improvement was greater than that observed among vehicle-treated patients (p < 0.05).

The research found that different companies have collaborated for the development of Sjögren’s syndrome.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/sjogrens-syndrome-therapeutics-pipeline-analysis/report-sample

Some of the key players developing drugs for Sjögren’s syndrome include Kissei Pharmaceutical Co., Ltd., UCB Group, Bristol-Myers Squibb Company and others.

Systemic Lupus Erythematosus Pipeline Analysis 2017

The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development. Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the immune system attacks its own tissues and can cause widespread inflammation and tissue damage in the affected organs. Some of the common symptoms of systemic lupus erythematosus include oral ulcers, sun sensitivity, heart problems, kidney problems, psychosis, lung problems, arthritis, seizures, fevers, skin rashes, fatigue, swelling and pain in the joints. Systemic lupus erythematosus is being treated using a combination approach as number of organs are involved. Therefore, various combination therapies are being used to improve quality of life of the patients. Also, combining novel drugs against different organs as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.

Explore Report Description at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis

Seattle Genetics, Inc. is using antibody-drug conjugate (ADC) technology platform for the development of Brentuximab vedotin for the treatment of systemic lupus erythematosus. The technology platform employs a monoclonal antibody specific for a tumor-associated antigen, plus synthetic cytotoxic (cell-killing) agents connected by stable linker systems designed to securely bind the cytotoxic agent to the antibody and then release the agent within the targeted cell.

The research also found that various companies have collaborated for the development of systemic lupus erythematosus pipeline.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample

Some of the key players developing drugs for systemic lupus erythematosus include Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA and others.

Pharmaceutical Membrane Technology Market Opportunities and Demand Forecast to 2023

Pharmaceutical Membrane Technology Market

Membrane technology is also widely used in improving water quality by removing particles, natural organic matter, pathogens (viruses and bacteria), emerging substances, and other dissolved matter from drinking water. Furthermore, membrane technology is used for the improvement of biological stability of drinking water in the distribution network. Water companies are legally forced to enhance the quality of drinking water in order to fulfill public health requirements. The enhancement is achieved by improving water quality and by operating water treatment processes more cost-efficiently with the help of membrane technology.

For more information visit: https://www.psmarketresearch.com/market-analysis/pharmaceutical-membrane-technology-market

Global pharmaceutical membrane technology market can be categorized on the basis of technology as ultrafiltration, reverse osmosis, microfiltration, chromatography and, nano filtration. Some of the major trends in the membrane technology market are product innovation and product portfolio expansion. The global membrane technology market is also going through large number of mergers, acquisitions and collaborations in recent years.

North America is the largest market for pharmaceutical membrane technology, owing to high concentration of pharmaceutical and biopharmaceutical manufacturing companies in the region. In Europe, many organizations, associations and societies are involved in development and implementation of membrane technology in pharmaceutical, biopharmaceutical and life sciences industries. However, Asia-Pacific is the fastest growing market for pharmaceutical membrane technology due to continuous development in pharmaceutical and biopharmaceutical industries. Additionally, increasing healthcare awareness, growing incidence of life style diseases, large population base and increasing government healthcare spending in developing countries of Asia-Pacific is driving the market for pharmaceutical membrane technology.

Request for Table of Content: https://www.psmarketresearch.com/market-analysis/Pharmaceutical-Membrane-Technology-Market/toc-sample

Some of the major competitors in global pharmaceutical membrane technology market are Amazon Filters Ltd., 3M Company, Pall Corporation, Advantec MFS Inc., Sartorius AG, GE Healthcare Life Sciences, Novasep, Merck Millipore (EMD Millipore), Koch Membrane Systems Inc., and TriSep Corporation.

Opioid-Induced Constipation Market Forecast to 2023

Opioid-Induced Constipation Market

Opioids are directed to the patients suffering from the acute and chronic non-cancer pain. The opioids have numerous adverse intestinal effects, such as opioid-induced constipation. The opioids also affect the discharge of digestive enzymes that can sometime cause partial gastro paresis. Some of the most familiar symptoms of opioid-induced constipation includes, hard and dry stools, swelling, painful defecation, distention and protruded abdomen, tiredness, and loss of hunger. Some of the most common opioid-induced constipation therapy is the use of targeted therapies, OTC and off-label drugs and changing lifestyle.

To Know More Visit: https://www.psmarketresearch.com/market-analysis/opioid-induced-constipation-market

Based on the drug action mechanism the global opioid induced constipation market can be segmented as: peripherally acting mu-opioid receptor antagonist, locally acting chloride channel activator, and others. Based on the administration route of drugs the global opioid-induced constipation market can be segmented into two broad categories: oral and parental.

Lack of awareness about the opioid-induced constipation in patients, and the doctors are one of the dominant causes of off-label and OIC medications as majorly used treatment methods. However, the efficiency of these drugs is only the half of some of the other therapies. The entrance of superficially acting mu-opioid receptor rivals such as Movantikv or Moventig are driving the opioid-induced constipation market. Movantikv or Moventig drug targets only the fundamental reason of opioid-induced constipation without affecting the effect of the opioid drugs.

Complicated treatment technology and lack of awareness regarding the upcoming treatment technology are some of the most dominant restrain for the opioid-induced constipation market. Cost effective research and development (R&D) in the development of new and effective treatment technology in the opioid-induced constipation market is one of the recent trend in the industry.

Request for Table of Content: https://www.psmarketresearch.com/market-analysis/Opioid-Induced-Constipation-Market/toc-sample

Some of the major players operating in the global opioid-induced constipation market include, AstraZeneca plc, Valeant Pharmaceuticals International Inc., Takeda Pharmaceutical Co. Ltd., Salix Pharmaceuticals, Ltd., Progenics Pharmaceuticals, Inc., Abbott Laborites, and Bayer AG among others.

Disinfectors Market Size, Share, Development and Demand Forecast to 2023

Disinfectors Market

Owing to the fact that cleaning and sanitation are vital for safety in the healthcare industries, the global market for disinfectants is driven by increased focus on hygiene and growing concerns over the spread of infectious diseases both at home and in public places. Rising demands in the food, beverage and healthcare industries is driving the global disinfectors market. Disinfectant chemicals are also becoming more common as an ingredient in various conventional and industrial cleaning products.

Explore Report at: https://www.psmarketresearch.com/market-analysis/disinfectors-market

Disinfectors are used for destroying pathogens for controlling infection.
Disinfection is an essential procedure that is performed for infection control in households and in healthcare facilities such as clinics, hospitals, elder care institutes and laboratories, using disinfectors and other infection control equipment such as sterilizers. Disinfectors are used to disinfect various medical instruments such as bedpans, surgical instruments, urine bottles and endoscopes. Disinfection is the process of destroying pathogenic organisms or rendering them inert. Hence, it ensures the hygiene condition of medical appliances that are used while providing medical services to people by healthcare workers.

The global disinfectant market can be categorized on the basis of disinfectors by product type, and disinfectors by applications. Based on disinfectors by product type, the global market for disinfectors is divided into washer, flusher and endoscope reprocessor. The washer is further divided into a single chamber (single door and double door) and multi chamber. On the basis of application, the global disinfectors market is classified into elder care, hospitals and clinics, and pharmaceuticals and life sciences.

Request for table of Content at: https://www.psmarketresearch.com/market-analysis/disinfectors-market/toc-sample

The rise in number of healthcare infrastructure in developing countries is one of the major trends in the disinfectors market. The large population in developing countries has opened up a large patient pool which eventually gives a rise in disposable income. The favorable economic conditions in most of the developing countries are propelling the infrastructural growth by establishing more medical care facilities and hospitals. Liquid products and aerosol are the most commonly used surface decontaminators, though a significant number of hospitals are employing UV disinfection systems as an surplus measure. Hence, another trend in the disinfectors market is the use of ultraviolet (UV) disinfectors as UV radiation inactivates micro-organisms by destroying the nucleic acids in viruses and bacteria.

Owing to the rise in number of chronic diseases, epidemic diseases such as H1N1 and aging population, North America dominates the disinfectors market followed by Europe.. Some of the major competitors in the global disinfectors market are Advanced Sterilization Products Division Ethicon US, LLC, Getinge AB, OLYMPUS CORPORATION and STERIS Corporation. Other prominent competitors in the market include ACTAVIS, American Biotech Labs, LLC, Amrep Inc, CareFusion Corporation, CCP Industries , Bio-Cide International, Inc., BIOTECHMEDICS US., Cantel Medical, Colgate-Palmolive Company., Swisher International, Inc., Diversey Inc.and many more.

 

Hypodermic Needle Market Analysis, Size, Development and Forecast to 2022

Hypodermic Needle Market

The global hypodermic needles market is expected to grow at a CAGR of 7.4% during 2016 – 2022. The growth of the global market is largely driven by the high demand for vaccines and increasing compliance of safety needles. High prevalence of needle stick injuries during drug administration is a key concern for healthcare providers across the globe. Improper disposal of syringe and needles is creating the demand for advanced safety mechanisms in hypodermic needles. Globally, approximately 16 billion injections are administered every year as per the World Health Organization (WHO); however, all the syringes and needles are not properly disposed of. Therefore, several benefits of safety needles such as ease of use during injection and safe delivery of drug or medication are increasing their popularity among healthcare providers.

Explore Report with Detailed TOC on “Global Hypodermic Needle Market” at: https://www.psmarketresearch.com/market-analysis/hypodermic-needles-market

Healthcare providers along with patients are getting aware about safety in drug delivery through syringes. This has created huge traction in the global market for developing advanced safety hypodermic needles with automatic features. Some of the other factors driving the growth of the global market include increasing prevalence of chronic and lifestyle associated diseases, and geriatric population. Increasing adoption of hypodermic needles in emerging economies is expected to create ample growth opportunities for the global market. However, alternative drug delivery method and high cost of hypodermic needles are the key barriers for the growth of the global market.

North America led the global hypodermic needle market in terms of size in 2015, owing to the increasing awareness of safe injectable technology, and increasing prevalence of chronic and lifestyle associated diseases. The U.S. contributed largest revenue to the North American as well as the global hypodermic needle market. The country is expected to remain the largest market for hypodermic needle globally during the forecast period.

Request For Sample Pages: https://www.psmarketresearch.com/market-analysis/hypodermic-needles-market/report-sample

Some of the players operating in the global market include Vygon S.A., Catalent, Inc., Terumo Corporation, Retractable Technologies, Inc., Connecticut Hypodermics, Inc., MedPro Safety Products Inc., B. Braun Melsungen AG, Albert David Ltd., Becton, Dickinson and Company, and Medtronic plc.

Ocular Pain Treatment Market Share, Development, Growth and Demand Forecast to 2023

The global ocular pain treatment market is expected to witness considerable growth due to increasing awareness about the eye disorders, technological advancement in ocular therapeutic and diagnostic test, and increasing number of lifestyle related ocular diseases. In addition, increasing geriatric population and increasing disposable income are further supporting the growth of the global ocular pain market.

The pharmaceutical companies are actively involved in the research and development of drugs for ocular pain. Loteprednol etabonate, a Mucus-Penetrating Particle platform technology based Phase III clinical trial drug of Kala Pharmaceuticals, Inc., is nanotechnology based products for the treatment of ocular pain.

Explore Full Report Description with Detailed TOC at: https://www.psmarketresearch.com/market-analysis/ocular-pain-treatment-market

Ocular pain is defined as the inflammation of middle layer of eye known as uvea. It can develop in optic nerve, blood vessels, muscles or other tissues that surround the eye.  Many factors such as infection, allergy, surgery or trauma including blow to the eye, foreign body and chemical injury can lead to ocular inflammation. It is important to manage ocular pain, else it can affect other parts of eyes such as cornea, retina, sclera, conjunctiva and the vasculature. Ocular pain is caused by several conditions such as glaucoma, ocular herpes, shingles, optic neuritis, dry eye and refractive error.

A large number of pharmaceutical companies are constantly working for the research and development of ocular pain treatment. However, certain factors such as high treatment cost, less awareness about the eye disease among population and lack of favorable government policy are the key factors hindering the growth of the global market during the forecast period.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/ocular-pain-treatment-market/toc-sample

Some of the key players operating in the global ocular pain market are ICON Bioscience Inc., Xigen S.A., Sylentis S.A., Bayer AG, Bristol Meyer Squibb Company, Merck and Co., Inc.,  Sun Pharmaceutical Industries Ltd., Reata Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc. and Ocular Therapeutix, Inc.

Personalized Medicine Market – Pipeline Analysis, Growth and Demand Forecast to 2023

Personalized Medicine Market

The global personalized medicine market is expected to witness significant growth due rapid advancement in diagnostic techniques, population heterogeneity across the globe, increasing awareness about the benefits of genetic makeup based drugs, and improving quality of disease diagnosis. The key vendors in the global personalized medicine market are focusing on oncology, infectious disease and cardiovascular targeted treatment and diagnostics.

Explore Full Report Description with Detailed TOC at: https://www.psmarketresearch.com/market-analysis/personalized-medicine-market

The pharmaceutical companies and biotechnology companies are actively involved in the research and development of personalized medicine. Different companies are developing and manufacturing biologics, such as blood products, vaccines, nutritional products, and gene therapies, to improve the quality of patient life. In December 2014, U.S. Food and Drug Administration (FDA) approved Lynparza, a poly (ADP-ribose) polymerase inhibitor as monotherapy in patients with deleterious or suspected deleterious germline breast cancer mutated advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy. Also in the same year, the organization approved the VIMIZIM, an enzyme replacement therapy for the treatment of patients with Morquio A syndrome.

National Cancer Institute, a part of the U.S. National Institutes of Health (NIH) defined personalized medicine as a form of medicine that uses information about a person’s genes, proteins and environment to prevent, diagnose and treat disease. In cancer, personalized medicine uses specific information about a person’s tumor to help diagnose, plan treatment, find out how well treatment is working, or make a prognosis. Personalized medicine uses targeted therapies to treat specific types of cancer cells, such as HER2-positive breast cancer cells, and to develop tumor marker for the diagnosis of cancer.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/personalized-medicine-market/toc-sample

Some of the key players operating in the global personalized medicine market are GE Healthcare, Illumina Inc., Quest Diagnostics Incorporated, Abbott, Affymetrix, Inc., Bayer AG, F. Hoffmann-La Roche AG, AstraZeneca PLC, Pfizer Inc., Valeant Pharmaceuticals International, Inc., and Vertex Pharmaceuticals Incorporated.

Uterine Fibroid Treatment Market Size, Share, Growth and Forecast to 2023

The global uterine fibroid treatment market is witnessing considerable growth due to increasing female geriatric population, increasing healthcare expenditure, increasing prevalence of obesity, launch of technologically advanced fibroid treatment products and growing popularity of minimally invasive treatments   minimally invasive treatments. Moreover, growing prevalence of hormonal disorders or hormonal imbalance leading to fibroid formation is supporting the growth of the market. The increasing adoption of uterine fibroid treatment across the globe, owing to increasing incidence of cancer is also driving the growth of the market.

Explore Report at: https://www.psmarketresearch.com/market-analysis/uterine-fibroid-treatment-market

The rapid growth in emerging economies and technological advancement in fibroid treatment with presence of minimally invasive treatment options is expected to create opportunities for the manufacturers of uterine fibroid treatment products. However, high cost of uterine fibroid treatment and presence of alternative treatment options are the key factors hampering the growth of the global market.

The increasing female aging population is propelling the growth of the global uterine fibroid treatment market. As reported by UN DESA (United Nation Department of Economic and Social Affairs) in the year 2013, the elder population is predominantly female. As women tend to live longer than men, while older women have outnumbered older men almost everywhere in the world. It further reported that in the year 2013, globally there were 85 men per 100 women in the age group 60 years or plus; and 61 men per 100 women in the age group 80 years or plus. The elderly population is more susceptible to gynecological problems, such as abnormal uterine bleeding, hormonal imbalance, and irregular menstrual cycle as compared to adults, which is fueling the demand of the global fibroid treatment market.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/uterine-fibroid-treatment-market/toc-sample

The key players operating in the global market are Boston Scientific Corporation, CooperSurgical, Inc., Karl Storz, Halt Medical, Inc., Merit Medical Systems, LiNA Medical USA, Olympus Corporation, and Richard Wolf GmbH.